Figure 3
Figure 3. B7 antigens, their ligands, and HLA-G on T cells. (A) Representative histogram of CD86 positive T cells. (B) Expression of increased CD80 (χ2 = 4.7; P < .02) and CD86 (χ2 = 15.3; P < .001) on peripheral blood CD3+ cells of patients with myeloma (n = 143) and an aged-matched control group (n = 20). (C) Expression of CD80 and (D) CD86 on peripheral blood CD4+ and CD8+ cells of patients with myeloma (n = 98) and an aged-matched control group (n = 10). (E) Expression of other B7 receptors and ligands involved at the immunologic synapse on CD3 cells of patients with myeloma and age-matched controls. (F) HLA-G expression on normal and myeloma patient T cells. Although expression is low, approximately 20% of myeloma patient's T cells express HLA-G above the age-matched range (dotted line, range 0.02%-0.56%; χ2 = 4.9; P < .03).

B7 antigens, their ligands, and HLA-G on T cells. (A) Representative histogram of CD86 positive T cells. (B) Expression of increased CD80 (χ2 = 4.7; P < .02) and CD86 (χ2 = 15.3; P < .001) on peripheral blood CD3+ cells of patients with myeloma (n = 143) and an aged-matched control group (n = 20). (C) Expression of CD80 and (D) CD86 on peripheral blood CD4+ and CD8+ cells of patients with myeloma (n = 98) and an aged-matched control group (n = 10). (E) Expression of other B7 receptors and ligands involved at the immunologic synapse on CD3 cells of patients with myeloma and age-matched controls. (F) HLA-G expression on normal and myeloma patient T cells. Although expression is low, approximately 20% of myeloma patient's T cells express HLA-G above the age-matched range (dotted line, range 0.02%-0.56%; χ2 = 4.9; P < .03).

Close Modal

or Create an Account

Close Modal
Close Modal